<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741962</url>
  </required_header>
  <id_info>
    <org_study_id>Adaptogen Study 001</org_study_id>
    <nct_id>NCT00741962</nct_id>
  </id_info>
  <brief_title>A Study on the Effects of VR-3 Herbal Blend Intake on Acute and Chronic Stress in Healthy Adults</brief_title>
  <official_title>A Pilot Double-Blind Crossover Study on the Effects of VR-3 Herbal Blend Intake on Acute and Chronic Stress and Their Biomarkers in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NEMA Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NEMA Research, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of VR-3 Herbal Blend and&#xD;
      its effects on acute and chronic stress responses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in salivary alpha-amylase and cortisol as stress biomarkers for the acute and chronic stress response following VR-3 Herbal Blend use</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in acute psychological stress</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in chronic stress</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VR-3 Herbal Blend</intervention_name>
    <description>This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women between the ages of 35-45&#xD;
&#xD;
          2. No health concerns as determined by study physicians&#xD;
&#xD;
          3. Women must not be pregnant or become pregnant for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject has a history of hypersensitivity to any of the compounds used in the&#xD;
             study&#xD;
&#xD;
          2. The subject is pregnant or a lactating female. Note: If the potential subject is a&#xD;
             post-menarcheal female, a pregnancy test (urine or serum) must be performed within 24&#xD;
             hours of study drug administration and confirmed negative in order for the potential&#xD;
             subject to be enrolled).&#xD;
&#xD;
          3. History of Psychiatric Illness or Chronic Stress or Anxiety&#xD;
&#xD;
          4. Hypertension, cardiovascular disease, or other health concerns that may confound study&#xD;
             results&#xD;
&#xD;
          5. Allergy or sensitivity to test product or ingredients&#xD;
&#xD;
          6. Individuals who are cognitively impaired or who are not able to give informed consent&#xD;
&#xD;
          7. Clinically significant or abnormal laboratory result that can confound the study&#xD;
&#xD;
          8. Medication or nutraceutical intake that can interact with the adaptogens or the&#xD;
             biomarkers used in the study (to be determined by study physician)&#xD;
&#xD;
          9. Previous participation in a clinical research trial within 30 days prior to&#xD;
             randomization&#xD;
&#xD;
         10. The subject has an ongoing abuse of illicit substances, alcohol, or actively smoking&#xD;
             marijuana.&#xD;
&#xD;
         11. The subject is actively engaging in the use of Herbal Medicine, Traditional Chinese&#xD;
             Medicine, Ancient Indian Medicine, Yoga, or Ayurveda&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NEMA Research</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <last_update_submitted>May 11, 2009</last_update_submitted>
  <last_update_submitted_qc>May 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ismail Shalaby, CEO</name_title>
    <organization>NEMA Research, Inc.,</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

